Ranked by reported Q4 2025 13F market value
Share of total reported institutional value in ANEB held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | 22NW, LP | 15.5M | $84.8M | 0.0% | 37.924% | 35.68% |
| 2 | Nantahala Capital Management, LLC | 3.0M | $3.1M | 0.0% | 7.445% | 0.12% |
| 3 | MANGROVE PARTNERS | 2.5M | $2.6M | 0.0% | 6.192% | 0.21% |
| 4 | VANGUARD GROUP INC | 436K | $440K | +42.2% | 1.069% | 0.00% |
| 5 | MORGAN STANLEY | 399K | $403K | 0.0% | 0.979% | 0.00% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 161K | $162K | -7.7% | 0.394% | 0.00% |
| 7 | Rangeley Capital, LLC | 50K | $51K | +150.0% | 0.123% | 0.05% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 25K | $25K | -11.9% | 0.061% | 0.00% |
| 9 | CITADEL ADVISORS LLC | 24K | $24K | — | 0.059% | 0.00% |
| 10 | BlackRock, Inc. | 24K | $24K | -1.1% | 0.058% | 0.00% |
| 11 | NORTHERN TRUST CORP | 22K | $22K | -9.8% | 0.054% | 0.00% |
| 12 | Ikarian Capital, LLC | 18K | $18K | -88.8% | 0.043% | 0.00% |
| 13 | STATE STREET CORP | 13K | $13K | 0.0% | 0.031% | 0.00% |
| 14 | Tower Research Capital LLC (TRC) | 3K | $3K | +84.6% | 0.008% | 0.00% |
| 15 | UBS Group AG | 2K | $2K | +960.9% | 0.006% | 0.00% |
| 16 | JPMORGAN CHASE & CO | 2K | $2K | +5.4% | 0.006% | 0.00% |
| 17 | BANK OF AMERICA CORP /DE/ | 382 | $386 | -57.1% | 0.001% | 0.00% |
| 18 | FNY Investment Advisers, LLC | 100 | $0 | — | 0.000% | 0.00% |
| 19 | ROYAL BANK OF CANADA | 30 | $0 | — | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ANEB — a direct measure of their conviction.
Filings activity in ANEB during Q4 2025, grouped by how each filer changed its position.
Institutions that fully closed their ANEB position in Q4 2025
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q4 2025 | 19 | 5.0% | 199.99% | +0.00 pp | $92M | +65% |
| Q3 2025 | 20 | +5.3% | 199.99% | +0.00 pp | $56M | +71% |
| Q2 2025 | 19 | +0.0% | 199.99% | +15.37 pp | $33M | +11% |
| Q1 2025 | 19 | +19% | 184.62% | 15.37 pp | $29M | 21% |
| Q4 2024 | 16 | +14% | 199.99% | +110.91 pp | $37M | +163% |
| Q3 2024 | 14 | +0.0% | 89.08% | 36.31 pp | $14M | 29% |
| Q2 2024 | 14 | 13% | 125.39% | 6.41 pp | $20M | 4.9% |
| Q1 2024 | 16 | — | 131.80% | — | $21M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying ANEB stock.
Based on Q4 2025 13F filings, institutional ownership of Anebulo Pharmaceuticals, Inc. stands at 200.0%, held across 19 reporting institutions.
22NW, LP is the largest reported institutional holder of ANEB, with approximately 15,467,300 shares worth $0.08B as of Q4 2025.
Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of ANEB, including RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for ANEB is 49 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in ANEB during Q4 2025, while 4 fully exited. 3 added to existing positions and 13 trimmed.
ANEB institutional ownership rose by 0.00 percentage points quarter-over-quarter, with a net change of -1 holders.
The top 10 institutions account for 99.9% of all reported 13F value in ANEB, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Anebulo Pharmaceuticals, Inc. (ANEB) Institutional Ownership